{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-24-000419","form_type":"8-K","ticker":"LNAI","cik":"0001527728","company_name":"Lunai Bioworks Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.503754+00:00","generated_at":"2026-06-04T22:13:53.801665+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Renovaro appoints Simon Tarsh as Interim CFO; outgoing CFO Puche departs","bullets":["Simon Tarsh named Interim CFO effective March 11, 2024; replaces Ms. Puche who leaves after >5 years.","Consulting agreement pays Tarsh PB Advisors $25,000/month plus up to 30% bonus on milestones.","Bonuses tied to timely SEC filings and hiring a permanent CFO before agreement termination.","Term is 6 months, renewable monthly; may be terminated by either party on 30 days' notice.","Tarsh receives 10,000 stock options, vesting if a new CFO is hired prior to termination date."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-24-000419","json":"https://secwatch.observer/filing/0001731122-24-000419.json","markdown":"https://secwatch.observer/filing/0001731122-24-000419.md","text":"https://secwatch.observer/filing/0001731122-24-000419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000419/0001731122-24-000419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000419/e5493_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:13:53.801665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"223b4ee847","claim":"Ms. Puche departed as Chief Financial Officer at Lunai Bioworks Inc..","evidence_excerpt":"Ms. Puche, the Company’s outgoing Chief Financial Officer, said: “After more than 5 years at the Company, I am ready for a new phase in my life.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000419/0001731122-24-000419-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"38f6fe43bb","claim":"Simon Tarsh was appointed as Interim Chief Financial Officer at Lunai Bioworks Inc..","evidence_excerpt":"The board of directors (the “Board”) of Renovaro Inc. (the “Company”) appointed Simon Tarsh, age 63, as Interim Chief Financial Officer of the Company, effective March 11, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000419/0001731122-24-000419-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}